首页> Clinical cancer research : an official journal of the American Association for Cancer Research> Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.

Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Andrew A,Davis

第一单位： Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, Missouri.

作者： Andrew A,Davis ^[1] ; Jingqin,Luo ^[2] ; Tiantian,Zheng ^[3] ; Chao,Dai ^[3] ; Xiaoxi,Dong ^[3] ; Lu,Tan ^[3] ; Rama,Suresh ^[1] ; Foluso O,Ademuyiwa ^[1] ; Caron,Rigden ^[1] ; Timothy P,Rearden ^[1] ; Katherine,Clifton ^[1] ; Katherine,Weilbaecher ^[1] ; Ashley,Frith ^[1] ; Pavan K,Tandra ^[4] ; Tracy,Summa ^[1] ; Brittney,Haas ^[1] ; Shana,Thomas ^[1] ; Leonel F,Hernandez-Aya ^[1] ; Lindsay L,Peterson ^[1] ; Xiaohong,Wang ^[3] ; Shujun J,Luo ^[3] ; Kemin,Zhou ^[3] ; Pan,Du ^[3] ; Shidong,Jia ^[3] ; Bonnie L,King ^[3] ; Jairam,Krishnamurthy ^[4] ; Cynthia X,Ma ^[1]

作者单位： Division of Oncology, Department of Medicine, Washington University School of Medicine in St. Louis, Missouri. ^[1] Division of Public Health Science, Department of Surgery, Biostatistics Shared Resource, Washington University in St. Louis, Missouri. ^[2] Predicine, Inc., Hayward, California. ^[3] Division of Oncology/Hematology, University of Nebraska Medical Center, Omaha, Nebraska. ^[4]